Stock Track | Hims & Hers Health Soars 5% on Bullish Outlook for Weight-Loss Drug Business

Stock Track12-06

Shares of Hims & Hers Health Inc. (HIMS) surged 5.06% in intraday trading on Friday, as investors cheered the company's potential for growth in the weight-loss drug market.

According to analysts at Canaccord Genuity, compounded versions of GLP-1 weight-loss drugs represent a high-growth revenue stream for telehealth firms like Hims & Hers in the near term. A survey conducted by the brokerage found that nearly half of the respondents interested in taking GLP-1 drugs were undecided between branded or compounded versions, leaving ample room for the compounded option to gain further adoption.

Notably, Hims & Hers was the most recognized telehealth platform among the survey respondents who expressed interest in using such a service to obtain GLP-1 treatment. The company's value proposition of providing affordable and easy access to medication and medical professionals aligns well with the key factors influencing respondents' selection of a telehealth platform.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1107436921?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-06 23:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107436921","market":"us","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 5% on Bullish Outlook for Weight-Loss Drug Business","media":"Stock Track","content":"<p>Shares of Hims & Hers Health Inc. (HIMS) surged 5.06% in intraday trading on Friday, as investors cheered the company's potential for growth in the weight-loss drug market.</p>\n\n<p>According to analysts at Canaccord Genuity, compounded versions of GLP-1 weight-loss drugs represent a high-growth revenue stream for telehealth firms like Hims & Hers in the near term. A survey conducted by the brokerage found that nearly half of the respondents interested in taking GLP-1 drugs were undecided between branded or compounded versions, leaving ample room for the compounded option to gain further adoption.</p>\n\n<p>Notably, Hims & Hers was the most recognized telehealth platform among the survey respondents who expressed interest in using such a service to obtain GLP-1 treatment. The company's value proposition of providing affordable and easy access to medication and medical professionals aligns well with the key factors influencing respondents' selection of a telehealth platform.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 5% on Bullish Outlook for Weight-Loss Drug Business</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 5% on Bullish Outlook for Weight-Loss Drug Business\n</h2>\n\n<h4 class=\"meta\">\n\n2024-12-06 23:41 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Hims & Hers Health Inc. (HIMS) surged 5.06% in intraday trading on Friday, as investors cheered the company's potential for growth in the weight-loss drug market.\nAccording to analysts at ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1107436921","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107436921","pubTimestamp":1733499668,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Hims & Hers Health Inc.  surged 5.06% in intraday trading on Friday, as investors cheered the company's potential for growth in the weight-loss drug market.According to analysts at Canaccord Genuity, compounded versions of GLP-1 weight-loss drugs represent a high-growth revenue stream for telehealth firms like Hims & Hers in the near term. A survey conducted by the brokerage found that nearly half of the respondents interested in taking GLP-1 drugs were undecided between branded or com","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票追踪Hims&Hers Health因减肥药业务前景乐观而飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Shares of Hims & Hers Health Inc. (HIMS) surged 5.06% in intraday trading on Friday, as investors cheered the company's potential for growth in the weight-loss drug market.\nAccording to analysts at Canaccord Genuity, compounded versions of GLP-1 weight-loss drugs represent a high-growth revenue stream for telehealth firms like Hims & Hers in the near term. A survey conducted by the brokerage found that nearly half of the respondents interested in taking GLP-1 drugs were undecided between branded or compounded versions, leaving ample room for the compounded option to gain further adoption.\nNotably, Hims & Hers was the most recognized telehealth platform among the survey respondents who expressed interest in using such a service to obtain GLP-1 treatment. The company's value proposition of providing affordable and easy access to medication and medical professionals aligns well with the key factors influencing respondents' selection of a telehealth platform.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107436921"}